Wednesday, July, 13th, 2022 at 11am EDT | 10am CDT | 8am PDT It’s no secret that hybrid and decentralized trials (DCT) are here to stay. Yet despite adoption, questions, myths, & rumors about what it means to “decentralize a trial,” persist. Find out the truth from Medable.
It’s no secret that hybrid and decentralized trials (DCT) are here to stay.
With EY-Parthenon reporting that more than 50% of trials will be decentralized by 2024, many sponsors and CROs are looking to gain the benefits of increased access to traditionally hard-to-reach patients, improved data, higher patient satisfaction, and more
Yet despite adoption, questions, myths, and rumors about what it means to “decentralize a trial,” persist.
Join us on July 13th at 11 AM EDT, as Andrew Mackinnon, VP & General Manager at Medable identify:
Key Learning Objectives:
Attendees will gain:
Who Should Attend:
Vice President & General Manager, eConsent
As General Manager for eConsent, Andrew Mackinnon oversees the development of the eConsent product, as well as the implementation of eConsent in Medable studies, ensuring that Medable’s clients can run high quality, effective and efficient decentralized clinical trials. Andrew has 20 years of experience in managing clinical trials at large Pharma, Biotech and CRO companies, most recently as a Senior Director in one of Covance’s therapeutic area delivery groups and as Head of Business Performance. From his involvement in one of the earliest deployments of decentralized methodologies, he has been passionate about the benefits that this approach can bring in reducing the burden of clinical research on both sites and patients and looks to leverage his broad operational expertise to improve how this approach is utilized.
John Galvin, MD, MS, MPH
Senior Medical Director, US Medical Affairs
Dr. John Galvin MD, MS, MPH is a hematologist in Chicago, IL and is Senior Medical Director, US Medical Affairs for Incyte Pharmaceuticals. Dr. Galvin is also affiliated with the University of Illinois Cancer Center. He has been in practice 11 years. He also has an affiliation with Northwestern University’s department of Immunology & Microbiology. He specializes in hematologic oncology with a focus on stem cell transplantation and graft versus host disease.